Work

Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.4095

Authors: Jonathan R. Strosberg, Jennifer A. Chan, Alain C. Mita, Madan Kundu, Sue-zette Valera, Peter Unge, Christelle Darstein, Mike Hu, Edward M. Wolin, James C. Yao

Institutions: Moffitt Cancer Center, Dana-Farber Cancer Institute, Cedars-Sinai Medical Center, Novartis (Switzerland), Novartis (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891624116

Cites:

Cited by:

Related to: 10